Menu Back toSession-2-Track-4-Ad-Promo

Regulatory Submissions, Information, and Document Management Forum

Session 2 Track 4: Ad/Promo

Session Chair(s)

Thomas  Noto

Thomas Noto

  • Senior Director, Regulatory Operations
  • Lexicon Pharmaceuticals, United States
AdPromo submissions in eCTD format are now being accepted, but are still the “new reality” for many sponsors. This session will focus on the changes to the eCTD that come with the new US Module 1 specification (DTD v.3.3) and key considerations for establishing an end-to-end process for AdPromo eCTD submissions. The session will also highlight real-world and tricks for transitioning to an efficient electronic 2253 submission workflow.
Learning Objective : Analyze and simplify the complexity of the new FDA requirements Address importance of guidance is to submission success Perform the process for creating eCTD submissions for OPDP Define the Dos and Don’ts of Submissions Differentiate when to include correspondence in your submission and when not to Recognize the advantages of working closely with the FDA on this and anticipate reactions


Sandra  Krogulski, MA

Submitting Ad Promo in eCTD: Tips and Tricks

Sandra Krogulski, MA

  • Associate Director, Submission Management
  • Bristol-Myers Squibb Company, United States
Thomas  Christensen, RAC

Lessons Learned for First-Time OPDP Submissions, Promotional Material, and Labeling

Thomas Christensen, RAC

  • Senior Regulatory Affairs Manager
  • SynteractHCR, United States
William  P Liston

Transitioning to eCTD for Ad Promo Submissions

William P Liston

  • Regulatory Associate - Submissions Specialist
  • Pfizer Inc., United States
Olga  Alfieri, MBA, MSc, RAC

Key Considerations in Establishing an End-to-End Process for FDA M1 AdPromo eCTD Submissions Process Prior to Implementation

Olga Alfieri, MBA, MSc, RAC

  • Director, Global Submission Management
  • Eisai Pharmaceuticals, United States